RNA Therapeutics Design Lead: siRNA & Oligo Optimization

Grünenthal Group; Wien; Hybrid; EUR 90.000 - 150.000; Vollzeit

Zusammenfassung

Grünenthal Group is seeking a senior researcher to lead design and computational optimisation of RNA therapeutics, focusing on siRNA design and integration of RNA biology with chemistry. You will drive iterative design cycles and develop scalable computational tools to accelerate discovery.

The role requires a PhD in RNA biology and 10+ years in industry, with strong Python or R skills and a track record in therapeutic pipeline advancement. Hybrid work model in Austria is expected.

Qualifikationen

• PhD in RNA biology with significant postdoctoral or industry experience.
• 10+ years in biotech/pharma, with antisense or siRNA design focus.
• Strong computational skills and data integration experience.
• Proven track record leading design-to-development programs.
• Experience working in matrixed teams and cross‑functional collaboration.

Aufgaben

• Lead design and computational optimisation of RNA therapeutics (siRNA) integrating biology and chemistry.
• Define target sites and design strategies using sequence features and data.
• Drive iterative design-test-learn cycles by integrating datasets to inform decisions.
• Develop computational tools/workflows (Python or R) for scalable design and data integration.
• Collaborate with chemists and delivery scientists to optimise sequence, chemistry and delivery.

Kenntnisse

RNA design

siRNA design

Computational biology

Bioinformatics

Cross-functional collaboration

Ausbildung

PhD in RNA biology

Tools

Python

R

Jobbeschreibung

Grünenthal Group is seeking a senior researcher to lead design and computational optimisation of RNA therapeutics, focusing on siRNA design and integration of RNA biology with chemistry. You will drive iterative design cycles and develop scalable computational tools to accelerate discovery.

The role requires a PhD in RNA biology and 10+ years in industry, with strong Python or R skills and a track record in therapeutic pipeline advancement. Hybrid work model in Austria is expected.